TABLE 2.
KEY PRODUCTS: SPECIALTY DRUG PIPELINE
| Drug | Use | Est. peak sales (millions) | Competitor drugs |
|---|---|---|---|
| 2007 launches | |||
| ambrisentan (Letairis) | Pulmonary arterial hypertension | $500 (global) | bosentan (Tracleer) |
| histrelin (Supprelin LA) | Precocious puberty | $28* | leuprolide (Lupron) |
| lapatinib (Tykerb) | Breast cancer | $1,200 (US) | trastuzumab (Herceptin) |
| nilotinib (Tasigna) | Chronic myeloid leukemia | $400* | dasatinib (Sprycel) |
| 2008 launches | |||
| certolizumab pegol (Cimzia) | Crohn’s disease | $525 (US) | infliximab (Remicade), adalimumab (Humira) |
| 2008 anticipated launches | |||
| icatibant (Firazir) | Hereditary angioedema | $100 (global) | First in class |
| eltrombopag (Promacta) | Idiopathic thrombocytopenia | $2,100* | First in class |
| tetrabenazine (Xenazine) | Huntington’s disease | N/A | First in class |
*
Market unspecified
Source: CVS 2007